Intel·Protein Powder

US Protein Powder on Meta: Fat Loss Claims, mTOR Language, and the Competitor-Naming Advertorial

DSHEA removes the EFSA constraint entirely. We pulled the active Meta libraries for Transparent Labs, Infinis Nutrition, and Apex Labs to show what protein advertising looks like when brands can say exactly what their product does.

AdIntel·21 October 2026·Meta Ad Library analysis

Key findings

  • Transparent Labs leads with a direct fat-and-muscle framing — “Lose the Fat. Not the Muscle.” — an outcome claim that would be prohibited under EFSA in Europe but runs without restriction under DSHEA in the US.
  • Infinis Nutrition operates at the mechanism level: “mTOR activation, the master switch for muscle growth,” named trademarked ingredients (Velositol®, Astragin®), and testosterone language — all DSHEA-compliant, none of it available to EU or UK brands.
  • Apex Labs runs a 600+ word competitor-naming advertorial that dismisses Optimum Nutrition Gold Standard, Transparent Labs, Nordic Naturals, and Kion Aminos by name, introduces the concept of “anabolic resistance” for people over 60, and positions its own product as the solution. Legal in the US. Illegal in the EU on multiple grounds.
  • The US/EU gap on protein creative is wider than any other supplement category we've tracked. The same product — whey protein — generates entirely different creative universes depending on which regulatory framework the brand operates under.

The Dietary Supplement Health and Education Act of 1994 — DSHEA — allows US supplement brands to make structure/function claims without FDA pre-approval. A brand can say its product “supports muscle growth,” “helps reduce body fat,” or “activates mTOR signaling” as long as it includes a standard disclaimer and notifies the FDA within 30 days of first use. The practical effect on Meta advertising is visible in the active libraries of the brands running right now. We pulled the creative for Transparent Labs, Infinis Nutrition, and Apex Labs to show what full-throttle protein advertising looks like when the regulatory constraint is removed.

Transparent Labs: fat and muscle as a binary

Transparent Labs' current Meta library runs a clear body composition frame. The hero creative is a direct outcome statement: “Lose the Fat. Not the Muscle.” This is the claim that defines the product's value proposition for the consumer: the protein is positioned not as a supplement that contributes to muscle maintenance (the EFSA formulation) but as a tool that actively separates fat loss from muscle loss — two outcomes in one product.

Transparent Labs · Primary campaign · Active

“Lose the Fat. Not the Muscle.”

Transparent Labs · US · ~20 active ads · Direct body composition outcome claim · DSHEA-compliant · Not available to EU/UK advertisers under EFSA

The creative runs without a mechanism explanation — the outcome is stated, not argued. Secondary creative in the library supports this with ingredient transparency messaging and third-party testing claims, which build trust for a consumer who has already been acquired by the outcome hook. The sequencing mirrors direct response best practices: lead with the result, justify with the proof.

Under EFSA, “Lose the Fat. Not the Muscle.” would fail on two grounds: it implies a fat-loss outcome (not an authorized claim for protein) and frames muscle retention as an active therapeutic result rather than a maintenance contribution with dose conditions. The same product, the same formula, the same creative intent — but only available in one market.

Infinis Nutrition: mechanism-level cellular claims

Infinis Nutrition operates at a different level of specificity. Its active Meta library names the cellular mechanism directly: “mTOR activation — the master switch for muscle growth.” The creative identifies the molecular pathway (mTOR), names the biological function (muscle protein synthesis), and frames the product as a direct activator of that pathway. This is mechanism-level advertising — not “supports muscle,” but “activates the switch.”

Infinis Nutrition · Mechanism creative · Active

“mTOR activation — the master switch for muscle growth.”

Infinis Nutrition · US · 8 active ads · Named trademarked ingredients: Velositol®, Astragin® · Testosterone language in secondary creative

The Infinis library also runs named trademarked ingredient claims — Velositol® (chromium-protein complex, licensed ingredient with clinical data) and Astragin® (absorption-enhancing compound) — and secondary creative that mentions support for “natural testosterone production.” The testosterone language in particular would be prohibited in the UK under MHRA guidance on supplements and sex hormones, and would have no authorized claim pathway under EFSA.

mTORThe mammalian target of rapamycin pathway — a legitimate cellular mechanism for muscle protein synthesis, which Infinis names directly in Meta ad copy. No EFSA authorized claim references mTOR. No EU or UK protein brand runs this language.

The trademarked ingredient strategy serves two functions simultaneously: it provides clinical data cover (Velositol® has peer-reviewed studies that the brand can cite) and it differentiates on ingredient quality in a way that generic “whey protein” positioning cannot. The mechanism + branded ingredient combination is a more defensible creative position than outcome-only claims — it invites a consumer who wants to understand what they're buying, not just what they'll look like after.

Apex Labs: the competitor-naming advertorial

The most distinctive creative in the US protein set is a long-form advertorial format run by Mike Jackson for Apex Labs. The active ads are 600+ words each — substantially longer than any other creative in the category — and structured as first-person editorial: a narrator who describes discovering the limitations of the protein market, names specific competing products, dismisses them, and arrives at Apex Labs as the solution.

The named competitors include Optimum Nutrition Gold Standard, Transparent Labs, Nordic Naturals, and Kion Aminos — all dismissed by name as inferior to Apex Labs' formulation. The advertorial introduces a concept called “anabolic resistance” — the idea that muscles become less responsive to protein signals after age 60 — and frames this as the mechanism that ordinary protein products fail to address.

Apex Labs / Mike Jackson · Advertorial format · Active

“Your muscles go resistant after 60 — and most protein products don't know it.”

Apex Labs · US · 3 active ads · 600+ words each · Names Optimum Nutrition Gold Standard, Transparent Labs, Nordic Naturals, Kion Aminos · “Anabolic resistance” concept · DSHEA-compliant

The advertorial format is a specific creative bet: it only works if a meaningful portion of the audience reads long copy on Meta. For a supplement brand targeting people over 60, this bet may be calibrated correctly — an older demographic that arrived on Facebook in 2012 and stayed, rather than migrating to shorter-form platforms, may be more receptive to editorial-length persuasion than a younger protein buyer would be.

In the EU, this creative would fail on at least three grounds: competitor naming in a disparaging context violates EU Comparative Advertising Directive requirements; “anabolic resistance” as a disease mechanism framing would require medical device or pharmaceutical authorization; and the structure/function claims embedded in the copy have no EFSA authorized claim pathway. In the UK, the ASA's CAP Code prohibits misleading comparative claims and requires that health claims be authorized under the GB NHC Register. The advertorial as written would not run.

What the US/EU gap means

The protein category is where the DSHEA/EFSA gap is most visible on Meta because the product is so directly tied to outcome claims — body composition, muscle growth, fat loss — that have no route through the EFSA authorized claim framework. US brands can lead with the result. EU and UK brands have to build entire creative strategies around the result they cannot name. The competitor gap is not about creative quality or budget. It's structural. A UK brand launching into the US market with its existing EU-compliant creative will be outclassed on persuasion by DSHEA-enabled competitors before it's even seen.

1

The fat/muscle binary is the most direct acquisition hook in the category

“Lose the Fat. Not the Muscle.” is a two-outcome claim in four words. It answers the primary objection to calorie restriction (muscle loss) and positions the product as the solution before the consumer has fully formed the question. This hook is not available to EU or UK brands under any EFSA authorized claim pathway. US brands enter the attention competition with a structural persuasion advantage.

2

Mechanism-level claims create a more defensible position than outcome-only

Infinis' mTOR framing does something outcome claims don't: it gives the consumer a reason-to-believe that doesn't depend on before/after photography or testimonials. A consumer who understands (or accepts) that mTOR governs muscle protein synthesis has a mechanism to attribute the result to. That attribution makes the purchase feel rational rather than aspirational — a different type of buyer, potentially with different LTV.

3

The competitor-naming advertorial is a format worth watching

The Apex Labs approach names competitors not to attack them but to dismiss them in a specific, credentialed way — each is identified as missing the anabolic resistance insight, not just generically inferior. This is a more sophisticated comparative move than price comparison or generic “better ingredients” language. Whether it converts at scale on Meta is unknown from the library alone, but three active ads suggests it's running long enough to be performing.

4

Global brands need two separate creative systems, not one adapted

A brand with distribution in both the US and UK cannot adapt US DSHEA creative for UK use by softening the outcome language — the structural elements that make the US creative work (outcome claims, mechanism language, competitor naming) are the elements that fail EU/UK compliance. The creative systems have to be built separately from the brief level. Brands that treat the EU adaptation as a compliance edit of US creative will end up with neither.

Related intelligence

For the EU and UK side of this story — how Myprotein, Form Nutrition, Free Soul, and Onyst navigate EFSA through flavor collabs, collagen bundling, and award positioning — see the EU & UK Protein Powder Meta Ads report.

Run your own

Want this kind of breakdown on your own competitor set? Snapshots pull any brand’s active Meta ads and structure the data for you.

See how Snapshots work →
← More Intel